{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:32:13Z","timestamp":1792794733654,"version":"4.5.0"},"reference-count":67,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T00:00:00Z","timestamp":1710115200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Pharmacosmos A\/S"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2024,12,31]]},"DOI":"10.1080\/13696998.2024.2313932","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T09:02:35Z","timestamp":1708678955000},"page":"392-403","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":11,"title":["Cost-utility analysis of ferric derisomaltose versus ferric carboxymaltose in patients with inflammatory bowel disease and iron deficiency anemia in England"],"prefix":"10.1080","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6681-9882","authenticated-orcid":false,"given":"Tariq H.","family":"Iqbal","sequence":"first","affiliation":[{"name":"Queen Elizabeth Hospital Birmingham","place":["Birmingham, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4368-1961","authenticated-orcid":false,"given":"Nicholas","family":"Kennedy","sequence":"additional","affiliation":[{"name":"Royal Devon and Exeter NHS Foundation Trust","place":["Exeter, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8964-2031","authenticated-orcid":false,"given":"Anjan","family":"Dhar","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, County Durham & Darlington NHS Foundation Trust","place":["Durham, UK"]},{"name":"School of Health and Life Sciences, Teesside University","place":["Teesside, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9035-7614","authenticated-orcid":false,"given":"Waqas","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Covalence Research Ltd","place":["Harpenden, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9873-7507","authenticated-orcid":false,"given":"Richard F.","family":"Pollock","sequence":"additional","affiliation":[{"name":"Covalence Research Ltd","place":["Harpenden, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,3,11]]},"reference":[{"key":"e_1_3_5_2_1","volume-title":"Inflammatory bowel disease. StatPearls","author":"McDowell C","year":"2023","unstructured":"McDowell C, Farooq U, Haseeb M. Inflammatory bowel disease. StatPearls. Treasure Island (FL): StatPearls Publishing; 2023."},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1159\/000496728"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2003.035758"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20285"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-8223(21)08097-4"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1159\/000452104"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000648"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2017.1263566"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/00365520310000771"},{"key":"e_1_3_5_11_1","unstructured":"Recombinant erythropoietin for the treatment of anemia in inflammatory bowel disease. PubMed [Internet]. [cited 2022 Oct 12]. Available at https:\/\/pubmed.ncbi.nlm.nih.gov\/8592524\/."},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.18773\/austprescr.2016.069"},{"key":"e_1_3_5_13_1","unstructured":"Joint United Kingdom (UK) Blood Transfusion and Tissue Transplantation Services Professional Advisory Committee. JPAC - transfusion guidelines. 2014. [cited 2022 Oct 12]. [Internet]. Available at https:\/\/transfusionguidelines.org.uk\/."},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S284959"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0000000000000329"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-020-01643-5"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S243462"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.22450"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25060"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.124486"},{"key":"e_1_3_5_21_1","unstructured":"Pharmacosmos A\/S. A randomized double-blinded comparative trial comparing the incidence of hypophosphatemia in relation to repeated treatment courses of iron isomaltoside and ferric carboxymaltose in subjects with iron deficiency anaemia due to inflammatory bowel disease. 2021. [Internet]. [cited 2022 Oct 11]. Available at https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03466983."},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-327897"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2021.116202"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfx310"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab852"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200969060-00007"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2016.1196496"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2022.2065092"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.114"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.11591\/ijece.v5i1.pp55-63"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01553-1"},{"key":"e_1_3_5_32_1","unstructured":"Table 12. Ganzoni formula for iron isomaltoside 1000 dosing [Internet]. Canadian Agency for Drugs and Technologies in Health; 2020. [cited 2023 Oct 31]. Available at https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK564172\/table\/pe.app5.tab4\/."},{"key":"e_1_3_5_33_1","first-page":"169","article-title":"Economic analysis during phase III clinical trials: who, what, when, where, and why","volume":"9","author":"Bennett CL","year":"1995","unstructured":"Bennett CL, Westerman IL. Economic analysis during phase III clinical trials: who, what, when, where, and why. Oncol Williston Park N. 1995;9:169\u2013175.","journal-title":"Oncol Williston Park N"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2019.1575202"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2020.07.002"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2021.1912010"},{"key":"e_1_3_5_37_1","unstructured":"WHO. Life tables by country (GHE: life tables). [Internet]. [cited 2022 Oct 21]. Available at https:\/\/www.who.int\/data\/gho\/data\/indicators\/indicator-details\/GHO\/gho-ghe-life-tables-by-country."},{"key":"e_1_3_5_38_1","volume-title":"Guide to the methods of technology appraisal 2013: process and methods [PMG9] [Internet]","author":"NICE","year":"2013","unstructured":"NICE. Guide to the methods of technology appraisal 2013: process and methods [PMG9] [Internet]. London and Manchester: National Institute for Health and Care Excellence; 2013. [cited 2022 Dec 5]. Available at https:\/\/www.nice.org.uk\/process\/pmg9\/resources\/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781."},{"key":"e_1_3_5_39_1","unstructured":"5 The reference case. | Guide to the methods of technology appraisal 2013 | Guidance | NICE [Internet]. NICE; [cited 2022 Oct 18]. Available at https:\/\/www.nice.org.uk\/process\/pmg9\/chapter\/the-reference-case."},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2020-11-3"},{"key":"e_1_3_5_41_1","unstructured":"Medicines and Healthcare products Regulatory Agency. Drug safety update: ferric carboxymaltose (Ferinject\u25bc): risk of symptomatic hypophosphataemia leading to osteomalacia and fractures [Internet]. GOV.UK; 2020. [cited 2021 Aug 12]. Available at https:\/\/www.gov.uk\/drug-safety-update\/ferric-carboxymaltose-ferinject-risk-of-symptomatic-hypophosphataemia-leading-to-osteomalacia-and-fractures."},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14643"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/ygh2.415"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0000000000001324"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-013-0066-1"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.2147\/PROM.S400389"},{"key":"e_1_3_5_47_1","volume-title":"National tariff payment system","author":"NHS England and NHS Improvement","year":"2022","unstructured":"NHS England and NHS Improvement. National tariff payment system. [Internet]. London: NHS England and NHS Improvement; 2022\/23. [cited 2022 May 26]. Available at https:\/\/www.england.nhs.uk\/publication\/national-tariff-payment-system-documents-annexes-and-supporting-documents\/."},{"key":"e_1_3_5_48_1","volume-title":"Unit costs of health and social care 2021","author":"Jones KC","year":"2021","unstructured":"Jones KC, Burns A. Unit costs of health and social care 2021. Kent, UK: Personal Social Services Research Unit; 2021."},{"key":"e_1_3_5_49_1","unstructured":"NICE. Phosphate [Internet]. [cited 2022 Oct 13]. Available at https:\/\/bnf.nice.org.uk\/drugs\/phosphate\/medicinal-forms\/."},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1186\/2046-4053-3-47"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13561-020-0260-8"},{"key":"e_1_3_5_52_1","unstructured":"NICE. Ferric derisomaltose. [Internet]. [cited 2022 Oct 13]. Available at https:\/\/bnf.nice.org.uk\/drugs\/ferric-derisomaltose\/medicinal-forms\/."},{"key":"e_1_3_5_53_1","unstructured":"NICE. Ferric carboxymaltose [Internet]. [cited 2022 Oct 13]. Available at https:\/\/bnf.nice.org.uk\/drugs\/ferric-carboxymaltose\/medicinal-forms\/."},{"key":"e_1_3_5_54_1","unstructured":"NHS Open Data Portal. Secondary Care Medicines Data (SCMD): important update. [Internet]. 2020. [cited 2023 Feb 27]. Available at https:\/\/opendata.nhsbsa.net\/dataset\/secondary-care-medicines-data."},{"key":"e_1_3_5_55_1","unstructured":"HCE. NHS Orders. [Internet]. [cited 2022 Oct 18]. Available at https:\/\/www.hce-uk.com\/NHS-Orders."},{"key":"e_1_3_5_56_1","unstructured":"NHS England. Improving non-emergency patient transport services: report of the non-emergency patient transport review; 2021. [Internet]. [cited 2023 Nov 27]. Available at https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2021\/08\/B0682-fnal-report-of-the-non-emergency-patient-transport-review.pdf."},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2022.09.1457"},{"key":"e_1_3_5_58_1","unstructured":"Office for National Statistics. Labour costs and labour income UK; 2023. [Internet]. [cited 2023 Nov 27]. Available at https:\/\/www.ons.gov.uk\/economy\/economicoutputandproductivity\/productivitymeasures\/datasets\/labourcostsandlabourshare."},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2020.1745535"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2020.1709437"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02242-x"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S306823"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/9991311"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14043"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-067003"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-174508"},{"key":"e_1_3_5_67_1","first-page":"19","article-title":"Symptomatic hypophosphataemia after intravenous iron therapy: an underrated adverse reaction","volume":"2019","author":"Ifie E","year":"2019","unstructured":"Ifie E, Oyibo SO, Joshi H, et\u00a0al. Symptomatic hypophosphataemia after intravenous iron therapy: an underrated adverse reaction. Endocrinol Diabetes Metab Case Rep. 2019;2019:19.","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"e_1_3_5_68_1","unstructured":"Davis S Stevenson M Tappenden P et\u00a0al. NICE DSU technical support document 15: cost-effectiveness modelling using patient-level simulation. Sheffield; 2014."}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2024.2313932","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T06:39:25Z","timestamp":1772779165000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2024.2313932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,11]]},"references-count":67,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12,31]]}},"alternative-id":["10.1080\/13696998.2024.2313932"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2024.2313932","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,11]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-10-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-17","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}